← Back to Search

Procedure

Electrophysiological Imaging for Ventricular Tachycardia (ECGI-VT Trial)

N/A
Recruiting
Led By John L Sapp, MD FRCPC
Research Sponsored by John Sapp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
One or more episodes of sustained monomorphic VT
Be older than 18 years old
Must not have
Are on IV inotropic agents
Had ST wave elevation myocardial infarction within < 1 month
Timeline
Screening 3 weeks
Treatment Varies
Follow Up less than 6 months post procedure
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new way to map and treat ventricular tachycardia, which contributes to over 350,000 sudden deaths each year in the US. The new method uses catheter ablation to "block" the channel that forms the circuit, with guidance from 3D images. The hope is that this will improve ablation efficacy and help clinicians identify ablation targets and assess ablation outcome.

Who is the study for?
This trial is for individuals who have had a heart attack or suffer from rapid, irregular heartbeats known as ventricular tachycardia and are scheduled for catheter ablation. Participants must have experienced sustained VT episodes, have an implantable cardioverter-defibrillator (ICD), and be able to follow the study's procedures. People with severe kidney issues, short life expectancy, listed for heart transplant, pregnant women, those on certain heart medications or with conditions that prevent MRI or CT scans cannot join.
What is being tested?
The trial is testing EP Imaging and Testing to improve treatment of ventricular tachycardia by using advanced imaging techniques combined with standard care. The goal is to better identify where in the heart's tissue electrical 'short circuits' occur before and after procedures like catheter ablation.
What are the potential side effects?
While specific side effects are not detailed here, typical risks may include discomfort at the imaging site, potential allergic reactions to contrast materials used in CT/MRI scans if applicable, and general risks associated with catheter ablation such as bleeding or infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had one or more episodes of a specific type of irregular heartbeat.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am receiving medication through an IV to strengthen my heart muscle.
Select...
I had a severe heart attack less than a month ago.
Select...
My doctor expects I have less than 6 months to live or I am on the heart transplant list.
Select...
I cannot or will not have a heart MRI or CT scan.
Select...
I cannot undergo catheter ablation due to certain health issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~less than 6 months post procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and less than 6 months post procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Termination of Ventricular Tachycardia
VT recurrence rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: EP Imaging and TestingExperimental Treatment1 Intervention
MRI images,120 lead body surface mapping and NIPS testing will be completed to correlate areas of VT scar.

Find a Location

Who is running the clinical trial?

John SappLead Sponsor
5 Previous Clinical Trials
712 Total Patients Enrolled
Nova Scotia Health AuthorityOTHER
288 Previous Clinical Trials
94,542 Total Patients Enrolled
Rochester Institute of TechnologyOTHER
11 Previous Clinical Trials
4,999 Total Patients Enrolled
John L Sapp, MD FRCPCPrincipal InvestigatorNova Scotia Health Authority
1 Previous Clinical Trials
416 Total Patients Enrolled

Media Library

EP Imaging and Testing (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03713866 — N/A
Ventricular Tachycardia Research Study Groups: EP Imaging and Testing
Ventricular Tachycardia Clinical Trial 2023: EP Imaging and Testing Highlights & Side Effects. Trial Name: NCT03713866 — N/A
EP Imaging and Testing (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03713866 — N/A
~6 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top